MA31393B1 - Anticorps anti-trop-2 humanisés et chimériques qui activent la cytotoxicité contre les cellules cancéreuses - Google Patents

Anticorps anti-trop-2 humanisés et chimériques qui activent la cytotoxicité contre les cellules cancéreuses

Info

Publication number
MA31393B1
MA31393B1 MA32371A MA32371A MA31393B1 MA 31393 B1 MA31393 B1 MA 31393B1 MA 32371 A MA32371 A MA 32371A MA 32371 A MA32371 A MA 32371A MA 31393 B1 MA31393 B1 MA 31393B1
Authority
MA
Morocco
Prior art keywords
antibodies
trop
monoclonal antibody
cancer
antibody
Prior art date
Application number
MA32371A
Other languages
Arabic (ar)
English (en)
Inventor
David S F Young
Helen P Findlay
Susan E Hahn
Cruz Luis A G Da
Alison L Ferry
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA31393B1 publication Critical patent/MA31393B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'expression de la trop-2, une protéine transmembranaire de près de 35 kda et un substrat de la protéine kinase c, a pu être associée à plusieurs cancers. La trop-2 est également connue en tant que ga733-1, glycoprotéine épithéliale 1 (egp-i) et transducteur 2 de signaux calciques associé aux tumeurs. Il a été démontré précédemment qu'un anticorps monoclonal contre la trop-2 provenant de l'hybridome ar47a6.4.2, déposé auprès de l'international depository authority of canada (idac) sous le numéro d'ordre 141205-05, est un anticorps modifiant les maladies cancéreuses (cdmab), qui inhibe la croissance tumorale et réduit la charge tumorale dans plusieurs types de cancers y compris celui de la prostate, du pancréas et du sein, par cytotoxicité. Les régions variables de cet anticorps monoclonal ont également été isolées, séquencées et des régions déterminant la complémentarité (crd) ont été déterminées. La présente invention porte sur un anticorps chimérique et des anticorps humanisés qui présentent une activité de liaison trop-2 similaire à celle de l'anticorps monoclonal parent 141205-05. Les anticorps monoclonaux, chimériques et humanisés peuvent être associés à des toxines, des enzymes, des composés radioactifs, des cytokines, des interférons, des fragments cibles ou rapporteurs et des cellules hématopoïétiques afin de traiter le cancer. Ces anticorps sont également utilisés dans des tests d'immunodétection en vue de détecter l'expression de trop-2 sur les cellules.
MA32371A 2007-05-30 2009-11-24 Anticorps anti-trop-2 humanisés et chimériques qui activent la cytotoxicité contre les cellules cancéreuses MA31393B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/807,837 US20080131428A1 (en) 2006-02-24 2007-05-30 Cytotoxicity mediation of cells evidencing surface expression of TROP-2
PCT/CA2008/000979 WO2008144891A1 (fr) 2007-05-30 2008-05-23 Anticorps anti-trop-2 humanisés et chimériques qui activent la cytotoxicité contre les cellules cancéreuses

Publications (1)

Publication Number Publication Date
MA31393B1 true MA31393B1 (fr) 2010-05-03

Family

ID=39476049

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32371A MA31393B1 (fr) 2007-05-30 2009-11-24 Anticorps anti-trop-2 humanisés et chimériques qui activent la cytotoxicité contre les cellules cancéreuses

Country Status (15)

Country Link
US (1) US20080131428A1 (fr)
EP (1) EP2155791A4 (fr)
JP (1) JP2010528056A (fr)
KR (1) KR20100003366A (fr)
CN (1) CN101679526A (fr)
AU (1) AU2008255528A1 (fr)
CA (1) CA2687586A1 (fr)
CO (1) CO6140062A2 (fr)
CR (1) CR11127A (fr)
EC (1) ECSP099770A (fr)
IL (1) IL202092A0 (fr)
MA (1) MA31393B1 (fr)
MX (1) MX2009012732A (fr)
WO (1) WO2008144891A1 (fr)
ZA (1) ZA200908346B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427665B2 (en) * 2000-12-08 2008-09-23 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) * 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US8075884B2 (en) * 2006-01-12 2011-12-13 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
JP2009544574A (ja) * 2006-06-22 2009-12-17 バクシネックス インコーポレーティッド 癌を処置するための抗ｃ３５抗体
WO2008074004A2 (fr) * 2006-12-14 2008-06-19 Medarex, Inc. Anticorps humains se liant à cd70 et utilisations de ceux-ci
AU2008279618B2 (en) * 2007-07-25 2014-05-22 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
AU2009339664B2 (en) * 2009-02-05 2014-12-04 Oncoxx Biotech S.R.L. Anti-Trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
CA2798778C (fr) * 2010-05-17 2016-01-05 Livtech, Inc. Anticorps anti-trop-2 humain ayant une activite anticancereuse in vivo
JPWO2011155579A1 (ja) * 2010-06-10 2013-08-15 北海道公立大学法人 札幌医科大学 抗Ｔｒｏｐ−２抗体
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CA2844042C (fr) * 2011-08-04 2019-06-18 Toray Industries, Inc. Composition pharmaceutique destinee a traiter ou a prevenir le cancer
CN104053672A (zh) 2011-11-11 2014-09-17 瑞纳神经科学公司 Trop-2特异性抗体及其用途
US9427464B2 (en) * 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
US20140357577A1 (en) * 2011-12-19 2014-12-04 Janssen R&D Limited HIV Membrane Fusion Inhibitors
ITCH20120008A1 (it) * 2012-05-16 2013-11-17 Saverio Alberti Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate
ES2703903T3 (es) 2013-12-25 2019-03-13 Daiichi Sankyo Co Ltd Conjugado de fármaco-anticuerpo anti-trop2
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
SG10202010936RA (en) 2014-02-21 2020-12-30 Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
CA2968330A1 (fr) 2014-12-04 2016-06-09 Abruzzo Theranostic S.R.L. Anticorps monoclonaux anti-pre-trop-2 humanises et leurs utilisations
KR20180021723A (ko) 2015-06-29 2018-03-05 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 선택적 제조 방법
CN104974988B (zh) * 2015-07-31 2016-08-24 南京麦科林生物医药科技有限公司 抗胰腺癌单克隆抗体及其应用
EP3518953A4 (fr) * 2016-09-29 2020-10-28 Aebi Ltd. Constructions thérapeutiques multi-ciblage et utilisations associée
TW201828993A (zh) 2016-12-12 2018-08-16 日商第一三共股份有限公司 抗體－藥物結合物與免疫檢查點抑制劑之組合
SG11201906554RA (en) 2017-01-17 2019-08-27 Daiichi Sankyo Co Ltd Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
EP3638296A1 (fr) 2017-06-16 2020-04-22 The University Of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
JP7248578B2 (ja) 2017-08-31 2023-03-29 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
SG11202000997YA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
BR112020007321A2 (pt) * 2017-10-20 2020-09-29 F. Hoffmann-La Roche Ag conjugado de anticorpo, uso, uso de um marcador isotópico estável e kit
DK3794042T3 (da) 2018-05-18 2024-04-15 Daiichi Sankyo Co Ltd Anti-muc1-exatecet-antistof-lægemiddelkonjugat
CN112739826A (zh) 2018-08-23 2021-04-30 第一三共株式会社 抗体-药物缀合物的敏感性标志物
WO2020094670A1 (fr) 2018-11-05 2020-05-14 Synaffix B.V. Anticorps-conjugués pour le ciblage de tumeurs exprimant trop -2
WO2020228604A1 (fr) * 2019-05-10 2020-11-19 江苏豪森药业集团有限公司 Anticorps anti-trop-2, fragment de liaison à l'antigène de celui-ci et utilisation médicale associée
CA3142119A1 (fr) 2019-05-29 2020-12-03 Daiichi Sankyo Company, Limited Dosage d'un conjugue anticorps-medicament pour le traitement du cancer
CN112390885B (zh) * 2019-08-12 2024-01-19 凯惠科技发展(上海)有限公司 一种trop2抗体及其制备方法、其偶联物和应用
US20230293716A1 (en) 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
WO2022036101A1 (fr) 2020-08-13 2022-02-17 Bolt Biotherapeutics, Inc. Immunoconjugués de pyrazoloazépine et leurs utilisations
WO2022204528A1 (fr) 2021-03-26 2022-09-29 Bolt Biotherapeutics, Inc. Immunoconjugués de 2-amino-4-carboxamide-benzazépine et utilisations associées
WO2022204536A1 (fr) 2021-03-26 2022-09-29 Bolt Biotherapeutics, Inc. Immunoconjugués de 2-amino-4-carboxamide-benzazépine et leurs utilisations
CA3234604A1 (fr) 2021-10-29 2023-05-04 Shelley Erin ACKERMAN Immunoconjugues agonistes de tlr avec des anticorps mutants de cysteine, et leurs utilisations
WO2023180485A1 (fr) 2022-03-23 2023-09-28 Synaffix B.V. Anticorps-conjugués pour le ciblage de tumeurs exprimant trop-2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7394296A (en) * 1995-10-19 1997-05-07 Bristol-Myers Squibb Company Monoclonal antibody br110 and uses thereof
DK3483183T3 (da) * 2002-03-01 2021-06-21 Immunomedics Inc Immunokonjugat omfattende humaniserede rs7-antistoffer
US7420040B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
CA2643063A1 (fr) * 2006-02-24 2007-08-30 Arius Research, Inc. Anticorps 141205-02 modifiant les maladies cancereuses

Also Published As

Publication number Publication date
AU2008255528A1 (en) 2008-12-04
ECSP099770A (es) 2009-12-28
CO6140062A2 (es) 2010-03-19
CR11127A (es) 2009-12-29
IL202092A0 (en) 2010-06-16
MX2009012732A (es) 2009-12-10
EP2155791A1 (fr) 2010-02-24
CA2687586A1 (fr) 2008-12-04
JP2010528056A (ja) 2010-08-19
KR20100003366A (ko) 2010-01-08
EP2155791A4 (fr) 2010-09-22
WO2008144891A1 (fr) 2008-12-04
US20080131428A1 (en) 2008-06-05
CN101679526A (zh) 2010-03-24
ZA200908346B (en) 2010-08-25

Similar Documents

Publication Publication Date Title
MA31393B1 (fr) Anticorps anti-trop-2 humanisés et chimériques qui activent la cytotoxicité contre les cellules cancéreuses
CA2855699C (fr) Anticorps anti-trop-2 humain presentant une activite antitumorale in vivo
US7854930B2 (en) Anti-igf-ir antibodies and uses thereof
EP2096122B1 (fr) Anticorps anti-humain specifiques de dlk1 presentant une activite anti-tumorale in vivo
JP5631733B2 (ja) 抗ＥｐＣＡＭ抗体およびその使用
US8017118B2 (en) Anti-hDlk-1 antibody having an antitumor activity in vivo
CN116655790A (zh) 抗tim-3抗体及其用途
KR101838310B1 (ko) 암의 치료를 위한 인간화 항-cxcr4 항체들
WO2003084569A1 (fr) Medicament contenant une composition anticorps
WO2008105560A1 (fr) Composition pharmaceutique comportant un anticorps anti-grp 78 en tant qu'ingrédient actif
KR20070107721A (ko) Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법
CN107849138B (zh) 抗Aggrus单克隆抗体及其应用
US20180142032A1 (en) Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
MX2009012606A (es) Anticuerpos anti-cd59 humanizados e hibridos que median citotoxicidad de celulas cancerosas.
EP2905335B1 (fr) Anticorps humain anti-dlk-1 ayant une activité anti-tumorale in vivo
Ohno et al. Production and characterization of highly tumor‐specific rat monoclonal antibodies recognizing the extracellular domain of human L‐type amino‐acid transporter 1
EP3939999A1 (fr) Anticorps neutralisant la sous-unité alpha du récepteur de l'interleukine 11 (il11ra) et leurs utilisations
AU2017391249B2 (en) Antibody or antibody fragment capable of binding to lung-specific X protein and use thereof
WO2023222068A1 (fr) Anticorps anti-cd200r1
CA3186062A1 (fr) Detection de mica et de micb a la surface de cellules a l'aide d'anticorps
CN116003604A (zh) 上皮钙黏素特异性抗体
JP2005089354A (ja) リン酸化されたβカテニンを選択的に認識する抗体